TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$0.26 USD
0.00 (1.12%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.26 0.00 (-0.50%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
TransCode Therapeutics Inc. [RNAZ]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Additional Data Noted From First Patient Dosed in TTX-MC138 Phase 0 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
IND Cleared for Phase 1/2 Study of TTX-MC138 in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
4Q23 Recap: Phase 1 TTX-MC138 Study Expected to Initiate in Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Data at SABCS Demonstrate That TTX-MC138 Is Delivered to Metastases in Phase 0 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Recap: Phase 0 Study Continues to Enroll Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 0 Study Confirms TTX-MC138 Traffics to Metastatic Lesions
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Recap: Phase 0 Study to Initiate Dosing Patients Soon; Phase 1/2 IND-Filing on Track for YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
TTX-MC138 Phase 0 Study to Initiate Imminently; Updating Model Post Reverse Stock Split
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
With TTX-MC138 eIND Cleared, the Company''s First Clinical Trial Is Set to Initiate in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
eIND Submission Puts TTX-MC138 One Step Closer to the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
3Q22 Take: eIND Filing on Track for 4Q22; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
2Q22 Take: eIND Filing and Phase 0 Initiation for TTX-MC138 is the Focus in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: TransCode Therapeutics Inc.
Industry: Medical - Drugs
Cracking the Code for Delivering RNA Therapeutics to Tumors; Initiating at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
|